{"transactions":[{"id":722911,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T23:00:04.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\") and R.A. Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":15000,"derivative":{"exercise_price":37.34,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-291051","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000119312526291051/ownership.xml","form_type":"4"}},{"id":740132,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-13T00:00:15.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":15500,"derivative":{"exercise_price":13.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001863094-26-000002","document":"form4-06122026_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000186309426000002/form4-06122026_080611.xml","form_type":"4"}},{"id":740131,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T00:00:15.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001863094-26-000002","document":"form4-06122026_080611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000186309426000002/form4-06122026_080611.xml","form_type":"4"}},{"id":741865,"issuer":{"id":3933,"kind":"organization","name":"Parabilis Medicines, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:47:53.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":20215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":20215,"derivative":{"exercise_price":20,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":20215},"source":{"system":"sec-edgar","filing":"0001193125-26-267766","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000119312526267766/ownership.xml","form_type":"4"}},{"id":743401,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:32:07.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":19475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\") and R.A. Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":19475,"derivative":{"exercise_price":20.56,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":19475},"source":{"system":"sec-edgar","filing":"0001628280-26-042247","document":"wk-form4_1781123521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026042247/wk-form4_1781123521.xml","form_type":"4"}},{"id":757230,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:10.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000119312526251537/ownership.xml","form_type":"4"}},{"id":1105145,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:40:10.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":16623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\") and R.A. Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":16623,"derivative":{"exercise_price":10.24,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":16623},"source":{"system":"sec-edgar","filing":"0000950170-25-088618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000095017025088618/ownership.xml","form_type":"4"}},{"id":1111950,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T23:30:11.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":11667,"derivative":{"exercise_price":25.46,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11667},"source":{"system":"sec-edgar","filing":"0001415889-25-017311","document":"form4-06132025_070603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588925017311/form4-06132025_070603.xml","form_type":"4"}},{"id":1111949,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T23:30:11.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001415889-25-017311","document":"form4-06132025_070603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588925017311/form4-06132025_070603.xml","form_type":"4"}},{"id":1116610,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T20:27:39.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\") and R.A. Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":23746,"derivative":{"exercise_price":11.48,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0002023658-25-000074","document":"wk-form4_1749587253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000074/wk-form4_1749587253.xml","form_type":"4"}},{"id":1127831,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:09.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000095017025080231/ownership.xml","form_type":"4"}},{"id":1406859,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-16T20:41:51.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\") and R.A. Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":23746,"derivative":{"exercise_price":18,"expiration_date":"2034-09-12","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0000950170-24-106880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000095017024106880/ownership.xml","form_type":"4"}},{"id":1467336,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T20:30:39.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":8350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":8350,"derivative":{"exercise_price":39.8,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":8350},"source":{"system":"sec-edgar","filing":"0001415889-24-018438","document":"form4-06282024_040635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588924018438/form4-06282024_040635.xml","form_type":"4"}},{"id":1467335,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-28T20:30:39.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option and RSUs reported on this Form 4 for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received upon exercise of the option or settlement of RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001415889-24-018438","document":"form4-06282024_040635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000141588924018438/form4-06282024_040635.xml","form_type":"4"}},{"id":1496811,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:30:13.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":18600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":18600,"derivative":{"exercise_price":15.94,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0000950170-24-067360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000095017024067360/ownership.xml","form_type":"4"}},{"id":1812135,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2023-08-09T20:36:43.000Z","date":"2023-08-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\") entered into the Agreement and Plan of Merger (the \"Merger Agreement\"), with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the \"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 9, 2023, each share of the Company's Common Stock,\npar value $0.0001 per share (\"Common Stock\"), was either (x) purchased for $48.00 per share (the \"Offer Price\"), without interest, less any\napplicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price,\nless any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the\nCommon Stock fully lapsed and all Common Stock became fully vested."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\"), became fully vested and exercisable (the \"Vested Option\").  Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company's Stock Option (the \"Option\") is fully vested and exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Under the Reporting Holder's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Holder holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Holder is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Holder therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":0,"derivative":{"exercise_price":14.98,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001209191-23-045189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919123045189/doc4.xml","form_type":"4"}},{"id":1852608,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:08:54.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Advisor\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":12500,"derivative":{"exercise_price":13.22,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-037984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919123037984/doc4.xml","form_type":"4"}},{"id":1870273,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T20:31:29.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":14500,"derivative":{"exercise_price":14.47,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-23-033780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919123033780/doc4.xml","form_type":"4"}},{"id":2230229,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T20:30:15.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":12500,"derivative":{"exercise_price":10.73,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-037424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919122037424/doc4.xml","form_type":"4"}},{"id":2231617,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T20:38:18.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders,  subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":14500,"derivative":{"exercise_price":5.38,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-22-036963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919122036963/doc4.xml","form_type":"4"}},{"id":2239237,"issuer":{"id":110693,"kind":"organization","name":"DICE Therapeutics, Inc.","symbol":"DICE"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-06-08T21:01:08.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Holder's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Holder holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Holder is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Holder therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":21250,"derivative":{"exercise_price":14.98,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001209191-22-035081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919122035081/doc4.xml","form_type":"4"}},{"id":2670456,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T21:40:25.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over the 36 months following June 10, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-040298","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000120919121040298/doc4.xml","form_type":"4"}}]}